Arrhythmias in Patients of Myocardial Infarction

Not yet recruiting

Conditions: ST elevation (STEMI) myocardial infarction of unspecified site,

Registration Number: CTRI/2022/12/048067

Lead Sponsor: ROHILKHAND MEDICAL COLLEGE AND HOSPITAL

Brief Summary: Cardiovascular Disease (CVD) in India has become the common cause of mortality in all parts of India including Rural and the poorer states. As compared to the western population CVD affects Indian population a decade earlier. It is has been seen that deaths due to CVD in India by 2020 have increased by 2.1 folds compared to the year 1990 and this is higher than mortality rate predicted in any other region of the world.

Acute Myocardial Infarction (AMI) is a clinical phase in the setting of myocardial ischemia with the evidence of myocardial injury . It is one of the commonest emergencies in the developed and developing countries. In the era prior to the use of fibrinolytic agents mortality due to acute MI was as high as 60 percent, which is more common within first twenty four hours, especially in the first hour. This high death rate was attributable to usually ventricular fibrillation.

There are disease which precipitates the cardiac complication like Diabetes, Hypertension, Dyslipidaemia, Hyperthyroidism Amongst which diabetes is one of the main cause. In AMI, cardiac arrhythmias are well-recognised, frequent complications and important predictors of mortality, which can be due to an imbalance of autonomic nervous system and electrolytes and also due to ischemia which causes conduction blockade in the infarcted zone. Conduction abnormalities especially high grade atrio- ventricular block is a common complication of ST-Elevation Myocardial Infarction (STEMI) and although in the era of primary percutaneous coronary intervention, the rates of post-myocardial infarction and the incidence of conduction abnormalities is low and decreasing, but it continues to be associated major factor for in hospital deaths.

Ventricular arrhythmias are common in the first 48 hours of infarction and continue to have a negative impact on the patientâ€™s outcome . The magnitude of risk of arrhythmias in AMI varies from patient to patient, with infarct size and left ventricular function being the most important risk stratified.

However in recent years, improvements in the diagnosis and treatment modalities has improved the outcomes associated with acute MI including the outcome of ventricular arrhythmias that occur following acute MI. These has led to significant fall in mortality associated with the complications of acute MI.

With limited data available in various parts of India, This study is planned to evaluate the incidence of arrhythmias and its prognostic significance in peri infarct period.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

Patients presenting within 48 hours of onset of symptoms suggestive of acute MI.
Patients with ECG changes suggestive of STEMI .
Acute MI patients with onset of arrythmia in 48 hours.
Patients with acute onset chest pain and TROP T positive within 48 hours of presentation.

Exclusion Criteria

Patients with past history of MI.
Patients with CAD on drugs.
Patients who are known cases of arrhythmias on treatment.
Patients with structural defects in the heart like Rheumatic Heart diseases and Congenital Heart diseases.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To study incidence and profile of different types of recent onset arrhythmias in acute STEMI	48 HOURS

Secondary Outcome Measures

Name	Time	Method
To study various types of arrhythmias in co relation to the wall involved on ecg.
To study various types of arrhythmias in co relation to time between the admission and the onset.	48 HOURS

Trial Locations

Locations (1): ROHILKHAND MEDICAL COLLEGE AND HOSPITAL
🇮🇳
Bareilly, UTTAR PRADESH, India
ROHILKHAND MEDICAL COLLEGE AND HOSPITAL
🇮🇳Bareilly, UTTAR PRADESH, India
DR MALINI KULSHRESTHA
Principal investigator
8218593127
dr.malinik@gmail.com